human control edta plasma samples (BioIVT Inc)
90
Structured Review
BioIVT Inc
human control edta plasma samples
Human Control Edta Plasma Samples, supplied by BioIVT Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+plasma+samples/edta+stabilized+human+plasma/pm39738845-48-0-13
Average 90 stars, based on 1 article reviews
Human Control Edta Plasma Samples, supplied by BioIVT Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/control+plasma+samples/edta+stabilized+human+plasma/pm39738845-48-0-13
Average 90 stars, based on 1 article reviews
human control edta plasma samples - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Clinical Proteomics:Article Title: Automated Sample Preparation Platform for Mass Spectrometry-Based Plasma Proteomics and Biomarker Discovery Article Snippet: .. EDTA-stabilized Article Title: Human and mouse non‐targeted metabolomics identify 1,5‐anhydroglucitol as SGLT2‐dependent glycemic marker Article Snippet: .. In addition to samples of the study, a 100 μL Article Title: Non‐targeted metabolomics identify polyamine metabolite acisoga as novel biomarker for reduced left ventricular function Article Snippet: Prior to analysis at the Helmholtz Zentrum München (Germany), samples were thawed on ice and randomized on the day of extraction. .. A 100 μL of the serum were pipetted into a 2 mL 96‐well plate together with 100 μL of Article Title: Deciphering metabolic shifts in Gaucher disease type 1: a multi-omics study. Article Snippet: Gaucher disease (GD), an autosomal recessive lysosomal disorder, primarily affects the lysosomal enzyme β-glucocerebrosidase (GCase), leading to glucosylceramide accumulation in lysosomes.. GD presents a wide spectrum of clinical manifestations.. This study deploys immune-based proteomics and mass spectrometry-based metabolomics technologies to comprehensively investigate the biochemical landscape in 43 deeply phenotyped type 1 GD patients compared to 59 controls. Article Title: Development and Characterization of Novel ELISAs for the Specific Quantification of the Factor H-Related Proteins 2, 3, 4, and 5 Article Snippet: A serum pool with known concentrations for FH, FHR-3, -4, and -5 was received from Sanquin Research (Sanquin Blood Supply Foundation, Amsterdam, the Netherlands) and used as a calibrator [ – ]. .. This serum pool was used to calibrate a pool of healthy Article Title: Development and characterization of novel ELISAs for the specific quantification of the factor H-related proteins 2, 3, 4 and 5. Article Snippet: A serum pool with known concentrations for FH, FHR-3, FHR-4 and FHR-5 was received from Sanquin Research (Sanquin Blood Supply Foundation, Amsterdam, The Netherlands) and used as a calibrator [28–30]. .. This serum pool was used to calibrate a pool of healthy other:Article Title: Qualitative improvement and quantitative assessment of N-terminomics. Article Snippet: Proteolysis represents one of the most tightly controlled physiological processes, as proteases create events that will typically commit pathways in an irreversible manner.. Despite their implication in nearly all biological systems, our understanding of the role of proteases in disease pathology is often limited.. Several approaches to studying proteolytic activity as it relates to biology, pathophysiology, and drug therapy have been published, including the recently described terminal amine isotopic labeling of substrates (TAILS) strategy by Kleifeld and colleagues. Article Title: Pharmacokinetics of vaginal versus buccal misoprostol for labor induction at term Article Snippet: Control:Article Title: Deciphering metabolic shifts in Gaucher disease type 1: a multi-omics study. Article Snippet: Gaucher disease (GD), an autosomal recessive lysosomal disorder, primarily affects the lysosomal enzyme β-glucocerebrosidase (GCase), leading to glucosylceramide accumulation in lysosomes.. GD presents a wide spectrum of clinical manifestations.. This study deploys immune-based proteomics and mass spectrometry-based metabolomics technologies to comprehensively investigate the biochemical landscape in 43 deeply phenotyped type 1 GD patients compared to 59 controls. |